Liraglutide tied to reduced progression of diabetic kidney disease

September 4, 2017

(HealthDay)—For patients with type 2 diabetes and high cardiovascular risk receiving usual care, the addition of liraglutide is associated with lower rates of development and progression of diabetic kidney disease, according to a study published in the Aug. 31 issue of the New England Journal of Medicine.

Johannes F.E. Mann, M.D., from the Friedrich Alexander University of Erlangen in Germany, and colleagues reported the prespecified renal outcomes of a involving with type 2 diabetes receiving usual care who were assigned to liraglutide or placebo. A total of 9,340 patients were randomized and followed for a median of 3.84 years.

The researchers found that the renal outcome (composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease) occurred in fewer participants in the liraglutide versus placebo group (268 of 4,668 versus 337 of 4,672 patients; hazard ratio, 0.78). This result was mainly driven by new onset of persistent macroalbuminuria, which occurred in 161 versus 215 patients in the liraglutide group versus (hazard ratio, 0.74). The rates of renal adverse events, including the rate of acute kidney injury, were similar in the groups.

"This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of than placebo," the authors write.

The study was partially funded by Novo Nordisk, the manufacturer of liraglutide.

Explore further: Liraglutide, sitagliptin have no effect on renal hemodynamics

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Liraglutide, sitagliptin have no effect on renal hemodynamics

September 9, 2016
(HealthDay)—In insulin-naive patients with type 2 diabetes, 12 weeks of treatment with liraglutide or sitagliptin has no effect on renal hemodynamics, according to a study published online Sept. 1 in Diabetes Care.

Valsartan cuts microalbuminuria in impaired glucose tolerance

February 9, 2017
(HealthDay)—For patients with impaired glucose tolerance (IGT), valsartan is associated with reduced incidence of microalbuminuria, according to a study published online Jan. 17 in Diabetes, Obesity and Metabolism.

Thiamine may reduce progression to renal replacement therapy

March 16, 2017
(HealthDay)—For patients in septic shock, thiamine is associated with a lower rate of progression to renal replacement therapy (RRT), according to research published online Feb. 16 in the Annals of the American Thoracic ...

CPAP doesn't alter renal function in coexisting OSA, CVD

August 11, 2017
(HealthDay)—For individuals with coexisting obstructive sleep apnea (OSA) and cardiovascular disease, continuous positive airway pressure (CPAP) does not alter renal function, according to a study published online July ...

Liraglutide increases heart rate in T2DM with stable CAD

October 25, 2016
(HealthDay)—Liraglutide increases heart rate (HR) and reduces heart rate variability (HRV) in overweight patients with newly diagnosed type 2 diabetes (T2D) and stable coronary artery disease (CAD), according to a study ...

Liraglutide augments weight loss in pre-type 2 diabetes

August 15, 2013
(HealthDay)—For patients at high risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD), liraglutide in additional to calorie restriction is associated with more weight loss and improvements in insulin ...

Recommended for you

Finding a natural defense against clogged arteries

September 20, 2017
In type 2 diabetes, chronic inflammation drives cardiovascular disease, the leading cause of death among people with the condition. Researchers at Joslin Diabetes Center now have identified an unexpected natural protective ...

Study identifies blood vessel as a therapeutic target for diabetes

September 14, 2017
Blood vessels have an often overlooked role of regulating the transfer of nutrients from the blood to organs in the body. In a new Yale-led study, researchers have identified a role of a secreted protein, apelin, in regulating ...

Drug for type 2 diabetes provides significant benefits to type 1 diabetic patients

September 14, 2017
A majority of patients with Type 1 diabetes who were treated with dapagliflozin, a Type 2 diabetes medicine, had a significant decline in their blood sugar levels, according to a new study published in The Lancet Diabetes ...

Could swine flu be linked to type 1 diabetes?

September 14, 2017
(HealthDay)—Young people who've been infected with the H1N1 swine flu virus may be at increased risk for type 1 diabetes, a new study suggests.

Epigenetic 'fingerprint' identifies diabetes risk

September 14, 2017
Deakin researchers have identified an epigenetic marker that predicts risk of type 2 diabetes in women with gestational diabetes.

Time to dial back on diabetes treatment in older patients? Study finds 11 percent are overtreated

September 14, 2017
Anyone with diabetes who takes blood sugar medication knows their doctor prescribed it to help them. After all, the long-term effects of elevated blood sugar can harm everything from the heart and kidneys to the eyes and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.